Skip to main content
    L

    Legend Biotech Corp (LEGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.99
    -1.51 (-8.63%)

    Market Cap: $3.39B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Legend Biotech Corp (LEGN) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Legend Biotech (LEGN) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Legend Biotech reported EPS of $0.28. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    38%(9/24)
    Avg Surprise
    -15.36%

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.04
    Range-$0.02 - $0.13
    14 analysts
    Revenue Consensus
    $389.25M
    Range$360.64M - $414.48M
    12 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.13
    Range$0.13 - $0.13
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.22-40.9%
    60d ago$0.130.0%
    30d ago$0.130.0%
    7d ago$0.130.0%
    Current$0.13
    Revenue Consensus
    $401.90M
    Range$380.00M - $443.19M
    3 analysts

    Next Report

    LEGN has an expected report date of Mar 8, 2027.

    LEGN Earnings Call

    The latest LEGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 24 quarters below that had an estimate, LEGN beat 9, missed 14 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $359.50M, up 32.0% from $272.33M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.28$0.01$0.01 - $0.01N/AN/AN/A10 up, 0 downNov 10, 2026$359.50M
    Jun 30, 2026$0.09$0.12N/A-25.00%MissN/A10 up, 0 downAug 11, 2026$387.50M
    Mar 31, 2026-$0.15$0.01N/AN/AN/AN/A10 up, 1 downMay 12, 2026$305.10M
    Dec 31, 2025-$0.16-$0.19-$0.19 - -$0.19+15.79%Beat-214.3%10 up, 0 downMar 10, 2026$306.38M
    Sep 30, 2025-$0.22-$0.18N/A-22.22%MissN/A41 up, 0 downNov 12, 2025$272.33M
    Jun 30, 2025-$0.68-$0.23-$0.24 - -$0.18-195.65%MissN/A31 up, 0 downAug 11, 2025$255.06M
    Mar 31, 2025-$0.54-$0.34-$0.42 - -$0.17-58.82%MissN/A100 up, 0 downMay 13, 2025$195.05M
    Dec 31, 2024$0.14-$0.38-$0.53 - -$0.15+137.24%BeatN/A50 up, 2 downMar 11, 2025$186.52M
    Sep 30, 2024-$0.68-$0.60-$0.64 - -$0.26-13.33%MissN/A71 up, 0 downNov 12, 2024$160.21M
    Jun 30, 2024-$0.10-$0.42-$0.68 - -$0.13+76.19%BeatN/A80 up, 0 downAug 9, 2024$186.52M
    Mar 31, 2024-$0.32-$0.32-$0.75 - -$0.080.00%In lineN/A70 up, 0 downMay 13, 2024$93.99M
    Dec 31, 2023-$0.80-$0.83-$1.48 - -$0.50+3.61%BeatN/A40 up, 1 downMar 11, 2024$79.46M
    Sep 30, 2023-$0.34-$0.74-$1.19 - -$0.26+54.05%BeatN/A52 up, 0 downNov 20, 2023$96.01M
    Jun 30, 2023-$1.14-$0.83-$1.13 - -$0.35-37.35%MissN/A71 up, 0 downAug 15, 2023$73.33M
    Mar 31, 2023-$0.68-$0.72N/A+5.56%BeatN/AN/AN/AMay 18, 2023$36.34M
    Dec 31, 2022-$0.82-$0.56-$0.94 - -$0.25-46.43%MissN/A102 up, 0 downMar 30, 2023$27.63M
    Sep 30, 2022-$0.89-$0.63-$0.86 - -$0.28-41.27%MissN/A100 up, 0 downNov 3, 2022$27.36M
    Jun 30, 2022-$0.33-$0.31-$0.61 - -$0.20-6.38%MissN/A90 up, 0 downAug 5, 2022$11.97M
    Mar 31, 2022-$0.49-$0.51-$0.83 - -$0.29+3.92%BeatN/A60 up, 1 downJun 1, 2022$41.33M
    Dec 31, 2021-$0.30-$0.41-$0.65 - -$0.30+26.83%BeatN/A62 up, 0 downMar 18, 2022$38.99M
    Sep 30, 2021-$0.86-$0.66N/A-30.30%MissN/A4N/ANov 16, 2021$17.04M
    Jun 30, 2021-$0.66-$0.43-$0.43 - -$0.30-53.49%MissN/A4N/AAug 23, 2021$20.83M
    Mar 31, 2021-$0.30-$0.35-$0.45 - -$0.33+14.29%BeatN/A3N/AMay 18, 2021$14.30M
    Dec 31, 2020-$0.44-$0.30-$0.30 - -$0.25-46.67%MissN/A3N/AMar 18, 2021$41.20M
    Sep 30, 2020-$0.50-$0.34-$0.37 - -$0.24-47.06%MissN/A3N/ANov 16, 2020$12.46M
    Jun 30, 2020-$0.51-$0.28-$0.31 - -$0.21-82.14%MissN/A3N/AAug 28, 2020$11.60M
    Mar 31, 2020-$0.51N/AN/AN/AN/AN/AN/AN/AJun 8, 2020$12.66M
    Dec 31, 2019-$0.64N/AN/AN/AN/AN/AN/AN/ADec 31, 2019$21.13M
    Sep 30, 2019-$0.28N/AN/AN/AN/AN/AN/AN/ASep 30, 2019$17.67M
    Jun 30, 2019-$0.29N/AN/AN/AN/AN/AN/AN/AJun 30, 2019$10.09M
    Mar 31, 2019-$0.12N/AN/AN/AN/AN/AN/AN/AMar 31, 2019$10.05M
    Last 31 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.60, after -$0.96 the year before. It was $0.07 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.60N/A
    Dec 31, 2024-$0.96N/A
    Dec 31, 2023-$2.96N/A
    Dec 31, 2022-$2.53N/A
    Dec 31, 2021-$2.12N/A
    Dec 31, 2020-$1.96N/A
    Dec 31, 2019-$1.01N/A
    Dec 31, 2018-$0.03-139.2%
    Dec 31, 2017$0.07N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,36618
    2026Q2Jun 30, 20266,16118
    2026Q1Mar 31, 20265,64718
    2025Q4Dec 31, 20257,37217
    2025Q3Sep 30, 20257,17215
    2025Q2Jun 30, 20257,14618
    2025Q1Mar 31, 20258,79120
    2024Q4Dec 31, 20247,87324

    2026Q3 Earnings Call

    Opening remarks

    Caroline LeCates Paul Senior Director of Investor Relations Good morning. This is Caroline Paul, Senior Director of Investor Relations at Legend Biotech. Thank you for joining us today to review our third quarter 2026 performance. Prior to this call, we issued a press release announcing our financial results, which can be found on the Legend Biotech Investor Relations website. Joining me on today's call are Ingrid Zhang, our Chief Executive Officer; Alan Bash, President of CARVYKTI; and Carlos Santos, Chief Financial Officer. Following the prepared remarks, we will open the call for Q&A. Yuhong Qiu, our Interim Head of R&D, will also join us for the Q&A session. During today's call, we will be making forward-looking statements, which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied here within. These forward-looking statements are discussed in greater detail in our SEC filings, which we encourage you to read and can be found under the Investors section of our company website. In addition, adjusted net income or loss is a non-IFRS metric. This non-IFRS financial measure is in addition to and not a substitute for or superior to measures of financial performance prepared in accordance with IFRS. There are a number of limitations related to the use of these non-IFRS financial measures versus their closest IFRS equivalents. However, we believe that providing information concerning adjusted net income or loss and adjusted net income or loss per share enhances an investor's understanding of our financial performance. Our press release includes IFRS to non-IFRS reconciliations for these measures. With that, I will now turn the call over to Ingrid.

    Ingrid Zhang Chief Executive Officer Thank you, Caroline, and good morning, everyone. Before reviewing our third quarter results, I'd like to share a few thoughts, as this is my first earnings call as Legend's CEO. Over the past several weeks, I have spent time with colleagues across the entire organization and engaged with physicians and other stakeholders working to bring CARVYKTI to patients around the world. What has become clear to me is the strength of what Legend has built. Legend has demonstrated its ability to bring innovative cell therapy to market at meaningful scale through strong science, manufacturing excellence, and a deep focus on patients. This is incredibly difficult to accomplish and speaks to the foundation that exists, which we can leverage for the rest of the pipeline. I've also been impressed by the quality of our people and the collaborative culture across the organization. Together, these strengths reinforce my confidence in Legend's future. I joined Legend because I believe the opportunity ahead is significant. CARVYKTI continues to expand its impact for patients with multiple myeloma.

    Frequently Asked Questions About LEGN

    When is Legend Biotech's next earnings date?

    Legend Biotech's next earnings report is expected for Mar 8, 2027.

    What EPS do analysts expect from LEGN next quarter?

    The consensus EPS estimate for Legend Biotech for the quarter ending Dec 31, 2026 is $0.04 from 14 analysts, with estimates from -$0.02 to $0.13.

    How often does LEGN beat earnings estimates?

    Legend Biotech beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -10.73%.